Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Monte Rosa Therapeutics (GLUE) EBIT: 2020-2024

Historic EBIT for Monte Rosa Therapeutics (GLUE) over the last 5 years, with Dec 2024 value amounting to -$81.1 million.

  • Monte Rosa Therapeutics' EBIT fell 24.31% to -$33.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.5 million, marking a year-over-year increase of 106.60%. This contributed to the annual value of -$81.1 million for FY2024, which is 43.40% up from last year.
  • Per Monte Rosa Therapeutics' latest filing, its EBIT stood at -$81.1 million for FY2024, which was up 43.40% from -$143.3 million recorded in FY2023.
  • Monte Rosa Therapeutics' 5-year EBIT high stood at -$28.0 million for FY2020, and its period low was -$143.3 million during FY2023.
  • Over the past 3 years, Monte Rosa Therapeutics' median EBIT value was -$112.4 million (recorded in 2022), while the average stood at -$112.3 million.
  • In the last 5 years, Monte Rosa Therapeutics' EBIT slumped by 160.20% in 2021 and then soared by 43.40% in 2024.
  • Over the past 5 years, Monte Rosa Therapeutics' EBIT (Yearly) stood at -$28.0 million in 2020, then tumbled by 160.20% to -$72.9 million in 2021, then crashed by 54.20% to -$112.4 million in 2022, then fell by 27.52% to -$143.3 million in 2023, then surged by 43.40% to -$81.1 million in 2024.